Financing ·
BioStem Technologies entered into a common stock purchase agreement with Roth Principal Investments on September 18…
BSEMBioStem Technologies, Inc.
BioStem Technologies entered into a common stock purchase agreement with Roth Principal Investments on September 18, 2026, establishing a committed equity facility allowing the company to sell up to $40 million of its common stock. The company holds sole discretion over the timing and amount of sales, which are subject to conditions including a minimum share price threshold of $1.00 and Nasdaq listing requirements. Roth Principal Investments is obligated to purchase shares only as directed by BioStem, with pricing based on volume-weighted average prices less fixed discounts ranging from 3.0% to 5.0%. The facility includes a registration rights agreement for the resale of up to 12,050,000 shares and requires the payment of a $400,000 cash commitment fee plus reimbursement of legal expenses. BioStem Technologies operates in the regenerative medicine industry, developing and commercializing perinatal tissue allograft products.